Epidemiology of growth hormone deficiency in children and adolescents: a systematic review.

IF 3 3区医学 Q2 ENDOCRINOLOGY & METABOLISM

Endocrine Pub Date : 2024-07-01 Epub Date: 2024-03-18 DOI:10.1007/s12020-024-03778-4

Chiara Mameli, Liliana Guadagni, Massimiliano Orso, Valeria Calcaterra, Malgorzata Gabriela Wasniewska, Tommaso Aversa, Simona Granato, Pietro Bruschini, Daniela d'Angela, Federico Spandonaro, Barbara Polistena, Gianvincenzo Zuccotti

{"title":"Epidemiology of growth hormone deficiency in children and adolescents: a systematic review.","authors":"Chiara Mameli, Liliana Guadagni, Massimiliano Orso, Valeria Calcaterra, Malgorzata Gabriela Wasniewska, Tommaso Aversa, Simona Granato, Pietro Bruschini, Daniela d'Angela, Federico Spandonaro, Barbara Polistena, Gianvincenzo Zuccotti","doi":"10.1007/s12020-024-03778-4","DOIUrl":null,"url":null,"abstract":"Objective: Growth hormone deficiency (GHD) is the most common pituitary hormone deficiency and is one of the main causes of short stature in children and adolescents. The aim of this study is to evaluate the epidemiology of pediatric GHD worldwide, since no other systematic review has been published so far.Methods: We searched PubMed, Embase, and Web of Science up to July 2023 to find epidemiological studies involving children with GHD. Two review authors independently screened articles, extracted data and performed the quality assessment.Results: We selected 9 epidemiological studies published from 1974 to 2022. The range of prevalence was 1/1107-1/8,646. A study based on a registry of GH users in the Piedmont region (Italy) reported the highest mean prevalence. In the included studies, the mean incidence ranged from 1/28,800 to 1/46,700 cases per year. One study reported a 20-year cumulative incidence of 127/100,000 for boys and 93/100,000 for girls. Studies were heterogeneous in terms of population (age and GHD etiology) and diagnostic criteria. As for the methodological quality of included studies, all but one study satisfied the majority of the checklist items.Conclusions: The included studies are mostly European, so the provided estimates cannot be considered global. International multicentre studies are needed to compare epidemiological estimates of GHD among different ethnical groups. Considering the considerable cost of human recombinant GH, the only available therapy to treat GHD, understanding accurate epidemiological estimates of GHD in each country is fundamental for resource allocation.","PeriodicalId":49211,"journal":{"name":"Endocrine","volume":null,"pages":null},"PeriodicalIF":3.0000,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11246253/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Endocrine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s12020-024-03778-4","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/3/18 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}

引用次数: 0

Abstract

Objective: Growth hormone deficiency (GHD) is the most common pituitary hormone deficiency and is one of the main causes of short stature in children and adolescents. The aim of this study is to evaluate the epidemiology of pediatric GHD worldwide, since no other systematic review has been published so far.

Methods: We searched PubMed, Embase, and Web of Science up to July 2023 to find epidemiological studies involving children with GHD. Two review authors independently screened articles, extracted data and performed the quality assessment.

Results: We selected 9 epidemiological studies published from 1974 to 2022. The range of prevalence was 1/1107-1/8,646. A study based on a registry of GH users in the Piedmont region (Italy) reported the highest mean prevalence. In the included studies, the mean incidence ranged from 1/28,800 to 1/46,700 cases per year. One study reported a 20-year cumulative incidence of 127/100,000 for boys and 93/100,000 for girls. Studies were heterogeneous in terms of population (age and GHD etiology) and diagnostic criteria. As for the methodological quality of included studies, all but one study satisfied the majority of the checklist items.

Conclusions: The included studies are mostly European, so the provided estimates cannot be considered global. International multicentre studies are needed to compare epidemiological estimates of GHD among different ethnical groups. Considering the considerable cost of human recombinant GH, the only available therapy to treat GHD, understanding accurate epidemiological estimates of GHD in each country is fundamental for resource allocation.

Abstract Image

查看原文本刊更多论文

儿童和青少年生长激素缺乏症的流行病学：系统回顾。

目的：生长激素缺乏症（GHD）是最常见的垂体激素缺乏症，也是导致儿童和青少年身材矮小的主要原因之一。本研究旨在评估全球范围内小儿生长激素缺乏症的流行病学，因为迄今为止还没有其他系统性综述发表：我们检索了截至 2023 年 7 月的 PubMed、Embase 和 Web of Science，以查找涉及 GHD 儿童的流行病学研究。两位综述作者独立筛选文章、提取数据并进行质量评估：我们选取了 1974 年至 2022 年间发表的 9 项流行病学研究。发病率范围为1/1107-1/8,646。一项基于意大利皮埃蒙特大区 GH 使用者登记的研究报告了最高的平均发病率。在所纳入的研究中，每年的平均发病率从1/28,800到1/46,700不等。一项研究报告称，20 年的累计发病率为：男孩 127/100,000，女孩 93/100,000。这些研究的研究对象（年龄和GHD病因）和诊断标准各不相同。至于纳入研究的方法学质量，除一项研究外，其他研究均符合检查表中的大多数项目：结论：纳入的研究多为欧洲研究，因此所提供的估计值不能被视为全球性的。需要开展国际多中心研究，以比较不同种族群体中高视力营养不良症的流行病学估计值。考虑到人类重组 GH（目前唯一可用于治疗 GHD 的疗法）的高昂费用，了解各国 GHD 的准确流行病学估计值对于资源分配至关重要。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Endocrine ENDOCRINOLOGY & METABOLISM-

CiteScore

6.50

自引率

5.40%

发文量

295

审稿时长

1.5 months

期刊介绍： Well-established as a major journal in today’s rapidly advancing experimental and clinical research areas, Endocrine publishes original articles devoted to basic (including molecular, cellular and physiological studies), translational and clinical research in all the different fields of endocrinology and metabolism. Articles will be accepted based on peer-reviews, priority, and editorial decision. Invited reviews, mini-reviews and viewpoints on relevant pathophysiological and clinical topics, as well as Editorials on articles appearing in the Journal, are published. Unsolicited Editorials will be evaluated by the editorial team. Outcomes of scientific meetings, as well as guidelines and position statements, may be submitted. The Journal also considers special feature articles in the field of endocrine genetics and epigenetics, as well as articles devoted to novel methods and techniques in endocrinology. Endocrine covers controversial, clinical endocrine issues. Meta-analyses on endocrine and metabolic topics are also accepted. Descriptions of single clinical cases and/or small patients studies are not published unless of exceptional interest. However, reports of novel imaging studies and endocrine side effects in single patients may be considered. Research letters and letters to the editor related or unrelated to recently published articles can be submitted. Endocrine covers leading topics in endocrinology such as neuroendocrinology, pituitary and hypothalamic peptides, thyroid physiological and clinical aspects, bone and mineral metabolism and osteoporosis, obesity, lipid and energy metabolism and food intake control, insulin, Type 1 and Type 2 diabetes, hormones of male and female reproduction, adrenal diseases pediatric and geriatric endocrinology, endocrine hypertension and endocrine oncology.

文献相关原料

公司名称	产品信息	采购帮参考价格